Neurogene(NGNE)
$22.93-0.21 (-0.91%)
NGNE
Neurogene stock drug pipeline
$22.93
At close:-0.21 (-0.91%)
Want to see NGNE full AI Analyst Report?
Neurogene (NGNE) Drug Pipeline
652 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ngn-401 | Rett Syndrome | phase1AndPhase2 | Recruiting | A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome | Jun 01, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ngn-401 | phase1AndPhase2 | Rett Syndrome | Recruiting | A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome | Jun 01, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Neurogene Inc. (NGNE) have in its pipeline
Neurogene NGNE is currently developing the following drugs: Ngn-401. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

